EMA Withdrawn: Evotopin (topotecan) — Beecham Group plc

View source ↗

Summary

EMA withdrawal of Evotopin (topotecan) from the market for ovarian neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Neoplasms

Drugs mentioned

• Evotopin (topotecan)

Snippet

Status: Withdrawn. Therapeutic area: Ovarian Neoplasms. MAH: Beecham Group plc. Decision date: 31/12/2009